BioSpace News Archive

CHI Franciscan and Virginia Mason continue to fulfill their commitment to expand women’s health care options with a new outpatient obstetric and women’s health clinic, Franciscan Women’s Health at Virginia Mason.

The Chief Public Health Officer and Government of Canada officials will hold a media availability to provide information on a novel coronavirus.

Cipher Pharmaceuticals Inc. announced the Company received a Notice of Termination from Bausch Health in connection with the License, Development and Commercialization Agreement of Trulance®.

The leading transcatheter heart valve medical device player in China - Venus Medtech Inc., is pleased to announce the appointment of two new cardiovascular experts to its advisory team.

Technavio has announced its latest market research report titled global gynecological cancers therapeutics market 2019-2023.

Medivir AB announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal Annals of Internal Medicine.

Canadian healthcare providers now have the tools they need to better support the prevention, assessment and treatment of older adults at risk of, or living with, substance use disorders

Hutchison China MediTech Limited announces that the independent Data Monitoring Committee of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors –pancreatic has completed a pre-planned interim analysis.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Donald A. Middlebrook has been named Vice President, Clinical, Regulatory and Quality, reporting directly to Chairman, CEO and President D. Keith Grossman.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of clinical utility data for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC, for patients diagnosed with high-risk cutaneous SCC.